{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:41:52Z","timestamp":1788385312333,"version":"build-2803163510"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Gaucher disease type 3 is a chronic neuronopathic disorder with wide-ranging effects, including hepatosplenomegaly, anaemia, thrombocytopenia, skeletal disease and diverse neurological manifestations. Biallelic mutations in GBA1 reduce lysosomal acid \u03b2-glucosidase activity, and its substrates, glucosylceramide and glucosylsphingosine, accumulate. Enzyme replacement therapy and substrate reduction therapy ameliorate systemic features of Gaucher disease, but no therapies are approved for neurological manifestations. Venglustat is an investigational, brain-penetrant, glucosylceramide synthase inhibitor with potential to improve the disease by rebalancing influx of glucosylceramide with impaired lysosomal recycling. The Phase 2, open-label LEAP trial (NCT02843035) evaluated orally administered venglustat 15 mg once-daily in combination with maintenance dose of imiglucerase enzyme replacement therapy during 1 year of treatment in 11 adults with Gaucher disease type 3. Primary endpoints were venglustat safety and tolerability and change in concentration of glucosylceramide and glucosylsphingosine in CSF from baseline to Weeks 26 and 52. Secondary endpoints included change in plasma concentrations of glucosylceramide and glucosylsphingosine, venglustat pharmacokinetics in plasma and CSF, neurologic function, infiltrative lung disease and systemic disease parameters. Exploratory endpoints included changes in brain volume assessed with volumetric MRI using tensor-based morphometry, and resting functional MRI analysis of regional brain activity and connectivity between resting state networks. Mean (SD) plasma venglustat AUC0-24 on Day 1 was 851 (282) ng\u2022h\/ml; Cmax of 58.1 (26.4) ng\/ml was achieved at a median tmax 2.00 h. After once-daily venglustat, plasma concentrations (4 h post-dose) were higher compared with Day 1, indicating \u223c2-fold accumulation. One participant (Patient 9) had low-to-undetectable venglustat exposure at Weeks 26 and 52. Based on mean plasma and CSF venglustat concentrations (excluding Patient 9), steady state appeared to be reached on or before Week 4. Mean (SD) venglustat concentration at Week 52 was 114 (65.8) ng\/ml in plasma and 6.14 (3.44) ng\/ml in CSF. After 1 year of treatment, median (inter-quartile range) glucosylceramide decreased 78% (72, 84) in plasma and 81% (77, 83) in CSF; median (inter-quartile range) glucosylsphingosine decreased 56% (41, 60) in plasma and 70% (46, 76) in CSF. Ataxia improved slightly in nine patients: mean (SD, range) total modified Scale for Assessment and Rating of Ataxia score decreased from 2.68 [1.54 (0.0 to 5.5)] at baseline to 1.55 [1.88 (0.0 to 5.0)] at Week 52 [mean change: \u22121.14 (95% CI: \u22122.06 to \u22120.21)]. Whole brain volume increased slightly in patients with venglustat exposure and biomarker reduction in CSF (306.7 \u00b1 4253.3 mm3) and declined markedly in Patient 9 (\u221213894.8 mm3). Functional MRI indicated stronger connectivity at Weeks 26 and 52 relative to baseline between a broadly distributed set of brain regions in patients with venglustat exposure and biomarker reduction but not Patient 9, although neurocognition, assessed by Vineland II, deteriorated in all domains over time, which illustrates disease progression despite the intervention. There were no deaths, serious adverse events or discontinuations. In adults with Gaucher disease type 3 receiving imiglucerase, addition of once-daily venglustat showed acceptable safety and tolerability and preliminary evidence of clinical stability with intriguing but intrinsically inconsistent signals in selected biomarkers, which need to be validated and confirmed in future research.<\/jats:p>","DOI":"10.1093\/brain\/awac379","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T22:03:38Z","timestamp":1665785018000},"page":"461-474","source":"Crossref","is-referenced-by-count":44,"title":["Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial"],"prefix":"10.1093","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-0252","authenticated-orcid":false,"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[{"name":"Institute of Metabolic Disease, Baylor Scott and White Research Institute , Dallas, TX 75246 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-9941","authenticated-orcid":false,"given":"Timothy M","family":"Cox","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge and Addenbrooke\u2019s Hospital , Cambridge CB2 0QQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dedieu","sequence":"additional","affiliation":[{"name":"Neurology Development, Sanofi , 91385 Chilly-Mazarin , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J M","family":"Gaemers","sequence":"additional","affiliation":[{"name":"Global Pharmacovigilance, Sanofi , Amsterdam, 1105 BP , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B","family":"Hennermann","sequence":"additional","affiliation":[{"name":"Center for Pediatric and Adolescent Medicine Villa Metabolica, University Medical Center Mainz , 55131 Mainz , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Jikei University School of Medicine , Tokyo 105-8461 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-2951","authenticated-orcid":false,"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[{"name":"Center for Pediatric and Adolescent Medicine Villa Metabolica, University Medical Center Mainz , 55131 Mainz , Germany"},{"name":"Clinical Science for LSD, SphinCS , 65239 Hochheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Minini","sequence":"additional","affiliation":[{"name":"Biostatistics and Programming, Sanofi , 91385 Chilly-Mazarin , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Mistry","sequence":"additional","affiliation":[{"name":"Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, Yale School of Medicine , New Haven, CT 06510 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra B","family":"Musholt","sequence":"additional","affiliation":[{"name":"R&D Global Development, Sanofi , 65926 Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Scott","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs, Neuroscience, Clario , San Mateo, CA 94404 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Sharma","sequence":"additional","affiliation":[{"name":"Pharmacokinetics, Dynamics and Metabolism, Sanofi , Bridgewater, NJ 08807 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Judith","family":"Peterschmitt","sequence":"additional","affiliation":[{"name":"Neurology Clinical Development, R&D, Sanofi , Cambridge, MA 02141 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"2023021318531336000_awac379-B1","volume-title":"OMMBID: The online metabolic and molecular bases of inherited disease","author":"Grabowski","year":"2013"},{"key":"2023021318531336000_awac379-B2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jimd.12235","article-title":"The definition of neuronopathic Gaucher disease","volume":"43","author":"Schiffmann","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"2023021318531336000_awac379-B3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: Revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"2023021318531336000_awac379-B4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","article-title":"Neuronopathic Gaucher disease: Demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry","volume":"33","author":"Tylki-Szymanska","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 1","key":"2023021318531336000_awac379-B5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/ajh.24063","article-title":"Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry","volume":"90","author":"Grabowski","year":"2015","journal-title":"Am J Hematol"},{"key":"2023021318531336000_awac379-B6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease","volume":"39","author":"Nilsson","year":"1982","journal-title":"J Neurochem"},{"key":"2023021318531336000_awac379-B7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol Genet Metab"},{"key":"2023021318531336000_awac379-B8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00690463","article-title":"Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies","volume":"65","author":"Conradi","year":"1984","journal-title":"Acta Neuropathol"},{"key":"2023021318531336000_awac379-B9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.410200208","article-title":"Type 2 and type 3 Gaucher disease: A morphological and biochemical study","volume":"20","author":"Kaye","year":"1986","journal-title":"Ann Neurol"},{"key":"2023021318531336000_awac379-B10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: Clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2023021318531336000_awac379-B11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol Genet Metab"},{"key":"2023021318531336000_awac379-B12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1067\/mpd.2001.112171","article-title":"The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher\u2019s disease","volume":"138","author":"Altarescu","year":"2001","journal-title":"J Pediatr"},{"key":"2023021318531336000_awac379-B13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2007.12.023","article-title":"Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease","volume":"153","author":"Goker-Alpan","year":"2008","journal-title":"J Pediatr"},{"key":"2023021318531336000_awac379-B14","doi-asserted-by":"crossref","first-page":"e2272","DOI":"10.1212\/WNL.0000000000008618","article-title":"Variation in cognitive function over time in Gaucher disease type 3","volume":"93","author":"Steward","year":"2019","journal-title":"Neurology"},{"key":"2023021318531336000_awac379-B15","doi-asserted-by":"crossref","first-page":"e22410","DOI":"10.1371\/journal.pone.0022410","article-title":"The saccadic and neurological deficits in type 3 Gaucher disease","volume":"6","author":"Benko","year":"2011","journal-title":"PLoS ONE"},{"key":"2023021318531336000_awac379-B16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"2023021318531336000_awac379-B17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann Neurol"},{"key":"2023021318531336000_awac379-B18","first-page":"1481","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355(9214)","author":"TL","year":"2000","journal-title":"Lancet"},{"key":"2023021318531336000_awac379-B19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible Inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol Ther"},{"key":"2023021318531336000_awac379-B20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023021318531336000_awac379-B21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: Development of a new clinical scale","volume":"66","author":"Schmitz-Hubsch","year":"2006","journal-title":"Neurology"},{"key":"2023021318531336000_awac379-B22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","article-title":"Trail Making Test A and B: Normative data stratified by age and education","volume":"19","author":"Tombaugh","year":"2004","journal-title":"Arch Clin Neuropsychol"},{"key":"2023021318531336000_awac379-B23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cortex.2017.07.021","article-title":"Processing speed and the relationship between trail making test-B performance, cortical thinning and white matter microstructure in older adults","volume":"95","author":"MacPherson","year":"2017","journal-title":"Cortex"},{"key":"2023021318531336000_awac379-B24","author":"CUP"},{"key":"2023021318531336000_awac379-B25","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J Clin Invest"},{"issue":"1-2","key":"2023021318531336000_awac379-B26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","article-title":"Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease","volume":"389","author":"Ghauharali-van der Vlugt","year":"2008","journal-title":"Clin Chim Acta"},{"key":"2023021318531336000_awac379-B27","doi-asserted-by":"crossref","first-page":"e0120194","DOI":"10.1371\/journal.pone.0120194","article-title":"Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease","volume":"10","author":"Zigdon","year":"2015","journal-title":"PLoS ONE"},{"issue":"4 suppl 5","key":"2023021318531336000_awac379-B28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"2023021318531336000_awac379-B29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"2023021318531336000_awac379-B30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014Initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"2023021318531336000_awac379-B31","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2023021318531336000_awac379-B32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0730-725X(99)00118-6","article-title":"Automatic measurement of changes in brain volume on consecutive 3D MR images by segmentation propagation","volume":"18","author":"Calmon","year":"2000","journal-title":"Magn Reson Imaging"},{"key":"2023021318531336000_awac379-B33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neuroimage.2013.05.039","article-title":"Resting-state fMRI in the human connectome project","volume":"80","author":"Smith","year":"2013","journal-title":"Neuroimage"},{"key":"2023021318531336000_awac379-B34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.neuroimage.2013.08.048","article-title":"Methods to detect, characterize, and remove motion artifact in resting state fMRI","volume":"84","author":"Power","year":"2014","journal-title":"Neuroimage"},{"key":"2023021318531336000_awac379-B35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fnsys.2011.00002","article-title":"A baseline for the multivariate comparison of resting-state networks","volume":"5","author":"Allen","year":"2011","journal-title":"Front Syst Neurosci"},{"key":"2023021318531336000_awac379-B36","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/hbm.21170","article-title":"Comparison of multi-subject ICA methods for analysis of fMRI data","volume":"32","author":"Erhardt","year":"2011","journal-title":"Hum Brain Mapp"},{"key":"2023021318531336000_awac379-B37","doi-asserted-by":"crossref","first-page":"13040","DOI":"10.1073\/pnas.0905267106","article-title":"Correspondence of the brain's functional architecture during activation and rest","volume":"106","author":"Smith","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023021318531336000_awac379-B38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/mrm.1910340409","article-title":"Functional connectivity in the motor cortex of resting human brain using echo-planar MRI","volume":"34","author":"Biswal","year":"1995","journal-title":"Magn Reson Med"},{"key":"2023021318531336000_awac379-B39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF01997792","article-title":"Trail making test: Normative values from 287 normal adult controls","volume":"17","author":"Giovagnoli","year":"1996","journal-title":"Ital J Neurol Sci"},{"key":"2023021318531336000_awac379-B40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/glia.20930","article-title":"Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice","volume":"58","author":"Saadat","year":"2010","journal-title":"Glia"},{"key":"2023021318531336000_awac379-B41","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1073\/pnas.96.16.9142","article-title":"A vital role for glycosphingolipid synthesis during development and differentiation","volume":"96","author":"Yamashita","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023021318531336000_awac379-B42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2023021318531336000_awac379-B43","first-page":"621","article-title":"Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease","volume":"35","author":"Pentchev","year":"1983","journal-title":"Am J Hum Genet"},{"key":"2023021318531336000_awac379-B44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/bj2690093","article-title":"Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease","volume":"269","author":"Aerts","year":"1990","journal-title":"Biochem J"},{"key":"2023021318531336000_awac379-B45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1432-1033.1985.tb08655.x","article-title":"Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase","volume":"146","author":"Vaccaro","year":"1985","journal-title":"Eur J Biochem"},{"key":"2023021318531336000_awac379-B46","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/oxfordjournals.jbchem.a124584","article-title":"The synthetic pathway for glucosylsphingosine in cultured fibroblasts","volume":"116","author":"Yamaguchi","year":"1994","journal-title":"J Biochem"},{"key":"2023021318531336000_awac379-B47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/EBC20190090","article-title":"Lyso-glycosphingolipids: Presence and consequences","volume":"64","author":"van Eijk","year":"2020","journal-title":"Essays Biochem"},{"key":"2023021318531336000_awac379-B48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jmedgenet-2019-106132","article-title":"Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy","volume":"57","author":"Kim","year":"2020","journal-title":"J Med Genet"},{"key":"2023021318531336000_awac379-B49","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ebiom.2018.11.037","article-title":"The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase","volume":"38","author":"Fog","year":"2018","journal-title":"EBioMedicine"},{"key":"2023021318531336000_awac379-B50","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/hmg\/ddz317","article-title":"Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes","volume":"29","author":"Massaro","year":"2020","journal-title":"Hum Mol Genet"},{"key":"2023021318531336000_awac379-B51","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.tp.0000181457.43146.36","article-title":"Allogeneic hematopoietic stem cell transplantation for inherited disorders: Experience in a single center","volume":"81","author":"Ringden","year":"2006","journal-title":"Transplantation"},{"key":"2023021318531336000_awac379-B52","first-page":"CD006974","article-title":"Hematopoietic stem cell transplantation for Gaucher disease","volume":"10","author":"Somaraju","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2023021318531336000_awac379-B53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08880018.2012.762076","article-title":"Gauchers disease\u2014A reappraisal of hematopoietic stem cell transplantation","volume":"30","author":"Ito","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"2023021318531336000_awac379-B54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/08880018.2013.793757","article-title":"Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease","volume":"30","author":"Machaczka","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"2023021318531336000_awac379-B55","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1186\/s13023-022-02378-7","article-title":"Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease","volume":"17","author":"Donald","year":"2022","journal-title":"Orphanet J Rare Dis."},{"key":"2023021318531336000_awac379-B56","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00234-018-2116-z","article-title":"Thalamic and dentate nucleus abnormalities in the brain of children with Gaucher disease","volume":"60","author":"Perucca","year":"2018","journal-title":"Neuroradiology"},{"key":"2023021318531336000_awac379-B57","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10545-011-9288-6","article-title":"Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging","volume":"34","author":"Davies","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"2023021318531336000_awac379-B58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejrad.2018.02.014","article-title":"Brain white matter microstructural alterations in children of type I Gaucher disease characterized with diffusion tensor MR imaging","volume":"102","author":"Kang","year":"2018","journal-title":"Eur J Radiol"},{"key":"2023021318531336000_awac379-B59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00234-018-2104-3","article-title":"Altered brain functional network in children with type 1 Gaucher disease: A longitudinal graph theory-based study","volume":"61","author":"Zhang","year":"2019","journal-title":"Neuroradiology"},{"key":"2023021318531336000_awac379-B60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JCP.0b013e3182825bfd","article-title":"Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease","volume":"33","author":"Sole-Padulles","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"2023021318531336000_awac379-B61","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/jmri.22662","article-title":"Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI","volume":"34","author":"Goveas","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"2023021318531336000_awac379-B62","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000450546","article-title":"Donepezil enhances frontal functional connectivity in Alzheimer's disease: A pilot study","volume":"6","author":"Griffanti","year":"2017","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"2023021318531336000_awac379-B63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/HRP.0000000000000179","article-title":"Ketamine-associated brain changes: A review of the neuroimaging literature","volume":"26","author":"Ionescu","year":"2018","journal-title":"Harv Rev Psychiatry"},{"key":"2023021318531336000_awac379-B64","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nn.3045","article-title":"Plasticity in gray and white: Neuroimaging changes in brain structure during learning","volume":"15","author":"Zatorre","year":"2012","journal-title":"Nat Neurosci"},{"key":"2023021318531336000_awac379-B65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/427311a","article-title":"Neuroplasticity: Changes in grey matter induced by training","volume":"427","author":"Draganski","year":"2004","journal-title":"Nature"},{"key":"2023021318531336000_awac379-B66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s002340050012","article-title":"MRI In acute neuropathic Gaucher's disease","volume":"42","author":"Chang","year":"2000","journal-title":"Neuroradiology"},{"key":"2023021318531336000_awac379-B67","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1212\/WNL.0000000000008673","article-title":"Linear vs volume measures of ventricle size: Relation to present and future gait and cognition","volume":"94","author":"Crook","year":"2020","journal-title":"Neurology"},{"key":"2023021318531336000_awac379-B68","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.trci.2019.05.007","article-title":"Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease","volume":"5","author":"Schwarz","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2023021318531336000_awac379-B69","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2023021318531336000_awac379-B70","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WAD.0b013e3182677b3d","article-title":"Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil\/vitamin E study","volume":"27","author":"Apostolova","year":"2013","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2023021318531336000_awac379-B71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s10194-018-0933-4","article-title":"Cognitive dysfunction and migraine","volume":"19","author":"Vuralli","year":"2018","journal-title":"J Headache Pain"},{"key":"2023021318531336000_awac379-B72","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1017\/S1355617709090626","article-title":"Construct validity of the Trail Making Test: Role of task-switching, working memory, inhibition\/interference control, and visuomotor abilities","volume":"15","author":"Sanchez-Cubillo","year":"2009","journal-title":"J Int Neuropsychol Soc"},{"issue":"3","key":"2023021318531336000_awac379-B73","first-page":"646","article-title":"Executive dysfunction","volume":"21","author":"Rabinovici","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"key":"2023021318531336000_awac379-B74","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: From pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J Bone Miner Res"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awac379\/47581803\/awac379.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/2\/461\/49171900\/awac379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/2\/461\/49171900\/awac379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T18:56:32Z","timestamp":1676314592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/146\/2\/461\/6763138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,18]]},"published-print":{"date-parts":[[2023,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awac379","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,10,18]]}}}